Compare DOCS & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOCS | ADPT |
|---|---|---|
| Founded | 2010 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 4.5B |
| IPO Year | 2021 | 2019 |
| Metric | DOCS | ADPT |
|---|---|---|
| Price | $33.38 | $25.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 21 | 9 |
| Target Price | ★ $30.44 | $29.81 |
| AVG Volume (30 Days) | ★ 2.8M | 2.0M |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $644,863,000.00 | $276,976,000.00 |
| Revenue This Year | $5.08 | $5.94 |
| Revenue Next Year | $6.70 | $22.42 |
| P/E Ratio | $259.31 | ★ N/A |
| Revenue Growth | 13.05 | ★ 54.77 |
| 52 Week Low | $17.15 | $12.00 |
| 52 Week High | $71.37 | $30.74 |
| Indicator | DOCS | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 70.65 | 46.87 |
| Support Level | $23.71 | $23.73 |
| Resistance Level | $40.00 | $26.51 |
| Average True Range (ATR) | 1.26 | 1.55 |
| MACD | 0.32 | -0.23 |
| Stochastic Oscillator | 84.97 | 21.68 |
Doximity Inc provides an online platform, which enables physicians and other healthcare professionals to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. The Company's customers include pharmaceutical companies and health systems that connect with healthcare professionals through the Company's digital Marketing, Hiring, and Workflow Solutions. Marketing Solutions provide customers with the ability to share tailored content on the network. Hiring Solutions enable customers to identify, connect with, and hire from the network of both active and passive potential medical professional candidates.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.